Related Experiment Video
Updated: Jun 19, 2026

Computerized Dynamic Posturography for Postural Control Assessment in Patients with Intermittent Claudication
Published on: December 11, 2013
A retrospective analysis on optimal medical therapy for patients with symptomatic lower extremity peripheral artery
Camille de Kermenguy1,2, Anne Durand1,2, Quentin Tollenaere1,2
1Vascular Medicine Unit, CHU Rennes, 2 Rue Henri Le Guilloux, Rennes, 35033, France.
Insights
Most lower extremity artery disease (LEAD) patients do not achieve LDL-cholesterol (LDLc) goals, with suboptimal medical treatment prevalence. Patients with a history of vascular surgery showed no improved management despite consistent follow-up.
Area of Science:
- Cardiovascular Medicine
- Vascular Surgery
- Pharmacology
Background:
- Symptomatic lower extremity artery disease (LEAD) management requires optimal lipid control (LDL-cholesterol [LDLc]) and medical therapy.
- The prevalence of LEAD patients achieving LDLc < 0.55 g/L and optimal medical treatment is not well-established.
- Optimal medical treatment includes triple therapy: antiplatelet, statin, and ACE inhibitor/ARB.
Purpose of the Study:
- To determine the prevalence of LEAD patients achieving LDLc < 0.55 g/L.
- To assess the prevalence of optimal medical treatment in LEAD patients.
- To compare management strategies between LEAD patients with and without a history of vascular surgery.
- To evaluate eligibility for novel lipid-lowering therapies (FOURIER and REDUCE-IT criteria).
Main Methods:
- Single-center retrospective study design.
- Prevalence calculated using numbers and percentages.
- Comparison of management between LEAD patients with and without prior vascular surgery.
- Calculation of patient eligibility for FOURIER (evolocumab) and REDUCE-IT (icosapent ethyl) studies.
Main Results:
- Only 12.4% of LEAD patients achieved LDLc < 0.55 g/L.
- Optimal medical treatment was received by 50.7% of patients.
- No significant difference in LDLc goal achievement between patients with (10.6%) and without (13.6%) vascular surgery history.
- 46.0% of patients were eligible for evolocumab and 8.4% for icosapent ethyl.
Conclusions:
- A significant majority of lower extremity artery disease patients do not meet LDL-cholesterol goals.
- LEAD patients with a history of vascular surgery did not demonstrate superior management outcomes.
- Despite more consistent follow-up, vascular surgery history did not correlate with better medical management in LEAD patients.
Objective:
Patients with symptomatic lower extremity artery disease (LEAD) should have an optimal management in terms of lipid goal [i.e. controlled LDL-cholesterol (LDLc)] and medical treatment (triple therapy with an antiplatelet agent, a statin and an angiotensin-converting enzyme inhibitor or a angiotensin-receptor antagonist). Prevalence of LEAD patients with a LDLc < 0.55 g/l is unknown. Aims of this study were to: (i) describe the prevalence of patients with a LDLc < 0.55 g/l, (ii) describe the prevalence of patients with an optimal medical treatment; (iii) compare this management between patients with a vascular surgery history and those without a vascular surgery history; and (iv) evaluate the number of patients eligible for new lipid-lowering therapies according to FOURIER and REDUCE-IT criteria.
Methods:
In this single-center retrospective study, prevalence is expressed as numbers and percentages. Comparison of the number of well managed patients between LEAD patients with a vascular surgery history and those without was performed. Number of patients who would be eligible for FOURIER and REDUCE-IT studies were calculated.
Results:
Among the LEAD patients included in the analysis (n = 225), only 12.4% (n = 28) had a LDLc < 0.55 g/L. The prevalence of patients who received the optimal medical treatment was 50.7% (n = 114). There was no statistical difference in the prevalence of patients with and without vascular surgery history achieving the LDLc goal (n = 9 (10.6%) vs. n = 19 (13.6%); p = not significant). Ninety-three patients (46.0%) would be eligible for EVOLOCUMAB treatment according to the Fourier study design whereas 17 patients (8.4%) would be eligible for treatment with ICOSAPENT ETHYL according to the REDUCE-IT study design.
Conclusion:
A majority of LEAD patients did not reach the LDLc goals. LEAD patients with a vascular surgery history did not experience a better management whereas they had a more consistent follow-up.
More Related Videos
07:25Predicting Amputation using Local Circulating Mononuclear Progenitor Cells in Angioplasty-treated Patients with Critical Limb Ischemia
Published on: September 22, 2020
13:48Reduction of Radiation Exposure during Endovascular Treatment of Peripheral Arterial Disease Combining Fiber Optic RealShape Technology and Intravascular Ultrasound
Published on: April 21, 2023
Related Concept Videos
Atherosclerosis IV: Nursing Management
Peripheral Artery Disease I: Introduction
Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation
Peripheral Artery Disease III: Interprofessional Care
Peripheral Artery Disease IV: Nursing Management
Peripheral Artery Disease V: Postoperative Nursing Management